University Cancer Research Fund
The University Cancer Research Fund (UCRF) is a nation-leading investment to stimulate cancer research and reduce North Carolina’s leading cause of death. The Fund builds upon the exceptional research base at UNC Lineberger Comprehensive Cancer Center, the state’s only public, NCI-designated comprehensive cancer center.
UCRF’s Goal
To create a nation-leading cancer research effort and to reduce North Carolina’s cancer burden. UCRF is accomplishing these goals through:
- Discovery to better understand the causes and course of cancer;
- Innovation to create new and better ways to prevent, diagnose and treat cancer; and by stimulating
- Delivery of improved cancer care, screening and prevention across the state.
Latest News
-
UNC Lineberger awards $1.35M for cancer research
UNC Lineberger awarded grants to 14 scientists and research teams in the fall grant awards cycle. Applications for the next round of funding will be due March 15.
-
Researchers publish milestone review on the role of cell signaling proteins in cancer
University of North Carolina Lineberger Comprehensive Cancer Center scientist Antonio “Tony” Amelio, PhD, is not necessarily looking for the “smoking gun” of cancer biology, or one single cause of cancer. Instead, he’s looking into how a family of newly described proteins involved in the cellular stress response can cause a complex ripple effect of changes … Continued
-
Researchers identify experimental immunotherapy approach to target acute myeloid leukemia
At the 60th American Society of Hematology Annual Meeting in San Diego on Dec. 3, Eben Lichtman, MD, presented preliminary findings from preclinical studies of CAR T-cells directed towards a potential target called B7-H3, which is found on the cell surface of certain types of AML.
-
Study shows promise for fighting relapsed blood cancer with CAR-T immunotherapy, chemotherapy
At the 60th American Society of Hematology Annual Meeting in San Diego on Monday, UNC Lineberger’s Natalie Grover, MD, presented preliminary results from a clinical study of an investigational cellular immunotherapy for Hodgkin lymphoma and non-Hodgkin lymphoma expressing the CD30 protein marker.
-
Scientists train a computer to classify breast cancer tumors
Using technology similar to the type that powers facial recognition on a smartphone, Charles M. Perou, PhD, Melissa Troester, PhD, and Heather D. Couture have trained a computer to analyze breast cancer images and then classify the tumors with high accuracy.